Related Experiment Videos
Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis
Panagiotis Katsinelos1, Jannis Kountouras, George Paroutoglou
1Department of Endoscopy and Motility Unit, Central Hospital, Thessaloniki, Greece.
Gastrointestinal Endoscopy
|July 2, 2005
Summary
Intravenous N-acetylcysteine (NAC) did not prevent post-ERCP pancreatitis in a clinical trial. This study found no significant difference in pancreatitis incidence or severity between NAC and placebo groups, indicating NAC is not beneficial for preventing this complication.
Area of Science:
- Gastroenterology
- Clinical Trials
- Medical Complications
Background:
- Acute pancreatitis is a common complication following Endoscopic Retrograde Cholangiopancreatography (ERCP).
- N-acetylcysteine (NAC) has shown potential in reducing experimental pancreatitis.
- This study investigated NAC's efficacy in preventing human post-ERCP pancreatitis.
Purpose of the Study:
- To evaluate the effectiveness of intravenous N-acetylcysteine (NAC) in preventing acute pancreatitis after ERCP.
- To determine if NAC influences the incidence or severity of post-ERCP pancreatitis.
Main Methods:
- A prospective, double-blind, placebo-controlled trial involving 256 patients undergoing ERCP.
- Patients received either intravenous NAC or a placebo.
- Clinical evaluation and serum amylase levels were monitored post-procedure to diagnose and grade pancreatitis.
Main Results:
- A total of 249 patients were analyzed; 10.8% developed post-ERCP pancreatitis.
- The incidence (12.1% NAC vs. 9.6% placebo) and severity of pancreatitis were not statistically different between groups.
- Hospitalization duration for pancreatitis was similar for both NAC and placebo groups.
Conclusions:
- Intravenous N-acetylcysteine (NAC) does not offer a beneficial effect in preventing or reducing the severity of ERCP-induced pancreatitis.
- The findings do not support the prophylactic use of NAC for post-ERCP pancreatitis.